AHOD Publications

Time trends in antiretroviral treatment use in Australia, 1997-2000. The Australian HIV Observational Database
Venereology 2001;14:162-168.

Rates of change of combination antiretroviral treatment in Australia
The Australian HIV Observational Database. HIV Medicine 2002;3:28-36. The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV Observational database
Petoumenos K on behalf of The Australian HIV Observational Database. Journal of Clinical Virology 2003;26:209-222. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral treatment
Lincoln D, Petoumenos K, Dore G on behalf of the Australian HIV Observational Database. HIV Medicine 2003;4:241-249. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database
Petoumenos K, Ringland C; on behalf of the Australian HIV Observational Database. HIV Medicine, 2005 May;6(3):155-63 Risk factors and causes of death in the Australian HIV Observational Database
K Petoumenos and M Law on behalf of the Australian HIV Observational Database. Sexual Health, 2006 May;3(2):103-12 Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment
K Falster, L Gelgor A Shaik, I Zablotska, G Prestage, J Grierson, R Thorpe, M Pitts, J Anderson, J Chuah, B Mulhall, K Petoumenos, A Kelleher, M Law. Sexual Health 2008;5:141-154. Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression.
Falster K, Petoumenos K, Chuah J, Mijch A, Mulhall B, Kelly M, Cooper DA on behalf of the Australian HIV Observational Database.Journal of Acquired Immune Deficiency Syndrome 2009 Mar; 50(3):307-313.

AHOD collaborative publications

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
The Plato Collaboration. Lancet. 2004 Jul 3;364(9428):51-62. Nucleoside Analogue Use Before and During Highly Active Antiretroviral Therapy and Virus Load Rebound
Collaboration of HIV Cohorts. JID 2004: 190 (15 August) - 675 Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts.
Calmy A, Petoumenos K, Lewden C, Law M, Bocquentin F, Hesse K, Cooper D, Carr A, Bonnet F (for the Aquitaine Cohort, Australian Oberservational Database and St Vincent’s Hospital Cohort study groups). HIV Medicine 2007;8:171-180. Long-term patterns in CD4 response is determined by an interaction between baseline CD4 cell count, viral load and time: The Asia Pacific HIV Observational Database (APHOD).
Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sugkanuparph S, Chuah J, Falster K, Zhou J, Law M, on behalf of the Asia Pacific HIV Observational Database. Journal of Acquired Immune Deficiency Syndrome 2009 April; 50(5): 513-520. AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment.
Falster K, Choi JY, Donovan B, Duncombe C, Mulhall B, Sowden D, Zhou J, Law MG on behalf of the Australian HIV Observational Database, the TREAT Asia HIV Observational Database. AIDS 2009 (epub ahead of print).

D:A:D Study publications

Modelling the three year risk of myocardial infarction among participants in the D:A:D study
Law M, Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O et al. HIV Med. 2003; 4(1):1-10. Cardiovascular risk factors in HIV patients - association with antiretroviral therapy Results from the DAD Study
Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA et al. AIDS. 2003,17:1179-1193 Lipid profiles in HIV-1-infected individuals receiving combination antiretroviral therapy: are different protease inhibitors or non-nucleoside reverse transcriptase inhibitors associated with different lipid profiles?
Fontas E, van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P. J Infect Dis. 2004;189(6):1056-1075 Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group
Writing Committee: Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD. N Engl J Med. 2003;349(21); 1993-2003. Cardio- and Cerebrovascular Events in HIV-Infected Persons. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group
Writing Committee: d'Arminio Monforte A, Sabin CA, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Phillips AN, Lundgren JD, and Friis-Moller N. AIDS 2004, 18:1811-1817 The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the DAD Study.
Writing Committee: Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D’Arminio Monforte A, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgen JD. HIV Medicine 2006;7:218-230 Liver-related deaths in persons infected with the human immunodeficiency virus.
Writing Committee: Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, D’Aminio Monforte A, Rickenbach M, Ledergerber B, Phillips AN Lundgren JD. Archives of Internal Medicine Class of antiretroviral drugs and the risk of myocardial infarction.
Writing Committee: Friis-Møller N, Reiss P, Sabin CA, Weber R, D’Arminio Monforte A, El-Sadr W, Thiebaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. The New England Journal of Medicine 2007;356:1723-35. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study.
De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, d’Arminio Monforte A, Fontas E, Law MG, Friis-Møller N, Lundgren JD. Diabetes Care. 2008 Jun;31(6):1224-9. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin CA , d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD. Clin Infect Dis. 2008 Apr 1;46(7):1101-10 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis f, De Wit S, Law M, D´Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Lancet. 2008 Apr 26;371(9622):1417-26. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.
The SMART/INSIGHT and the D:A:D study groups. Lundgren JD, Neuhaus J, Babiker A, Cooper D, Duprez D, El-Sadr W, Emery S, Gordin F, Kowalska J, Phillips A, Prineas RJ, Reiss P, Sabin C, Tracy R, Weber R, Grund B and Neaton JD. AIDS.2008, 22:F17-F24. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. AIDS. 2008 Oct 18;22(16):2143-53 Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the DATA Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).
Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Møller N. Circulation. 2009 Feb 17;119(6):805-11. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D study).
Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte A, Pradier C, Thiebaut R, Law M, Richenbach M, De Wit S, Lundgren JD, Friis-Møller N. Diabetes Care. 2009 Mar;32(3):474-80.